Why the study?
Few studies have compared the associations between diabetes mellitus and cardiac remodeling, quality of life, and clinical outcomes according to heart failure phenotype.
Does type 2 diabetes mellitus worsen cardiac remodeling, quality of life, and clinical outcomes in patients with HFrEF and HFpEF?
Does type 2 diabetes mellitus worsen cardiac remodeling, quality of life, and clinical outcomes in patients with HFrEF and HFpEF?
Type 2 diabetes mellitus is associated with adverse cardiac remodeling, poorer quality of life, and worse 1-year clinical outcomes in both HFrEF and HFpEF patients.
Answers are grounded in this paper and cite their sources.
Diabetes links to adverse remodeling, poorer QoL, and worse outcomes across HF phenotypes; leaves open targeted interventions.
Background Diabetes mellitus frequently coexists with heart failure ( HF ), but few studies have compared the associations between diabetes mellitus and cardiac remodeling, quality of life, and clinical outcomes, according to HF phenotype. Methods and Results We compared echocardiographic parameters, quality of life (assessed by the Kansas City Cardiomyopathy Questionnaire), and outcomes (1‐year all‐cause mortality, cardiovascular mortality, and HF hospitalization) between HF patients with and without type 2 diabetes mellitus in the prospective ASIAN ‐ HF (Asian Sudden Cardiac Death in Heart Failure) Registry, as well as community‐based controls without HF . Adjusted Cox proportional hazards models were used to assess the association of diabetes mellitus with clinical outcomes. Among 5028 patients with HF and reduced ejection fraction ( HF r EF ; EF <40%) and 1139 patients with HF and preserved EF ( HF p EF ; EF ≥50%), the prevalences of type 2 diabetes mellitus were 40.2% and 45.0%, respectively ( P =0.003). In both HF r EF and HF p EF cohorts, diabetes mellitus (versus no diabetes mellitus) was associated with smaller indexed left ventricular diastolic volumes and higher mitral E/e′ ratio. There was a predominance of eccentric hypertrophy in HF r EF and concentric hypertrophy in HF p EF . Patients with diabetes mellitus had lower Kansas City Cardiomyopathy Questionnaire scores in both HF p EF and HF r EF , with more prominent differences in HF p EF ( P interaction <0.05). In both HF p EF and HF r EF , patients with diabetes mellitus had more HF rehospitalizations (adjusted hazard ratio, 1.27; 95% CI , 1.05–1.54; P =0.014) and higher 1‐year rates of the composite of all‐cause mortality/ HF hospitalization (adjusted hazard ratio, 1.22; 95% CI , 1.05–1.41; P =0.011), with no differences between HF phenotypes ( P interaction >0.05). Conclusions In HF p EF and HF r EF , type 2 diabetes mellitus is associated with smaller left ventricular volumes, higher mitral E/e′ ratio, poorer quality of life, and worse outcomes, with several differences noted between HF phenotypes. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 01633398.
No takes yet. Share an insight, caveat, or question.
Yap et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: